BioMarin Pharmaceutical (BMRN) fundamentals: P/E, valuation, undervalued?
BioMarin Pharmaceutical · Health Care · ref. ETF XLV · price $54.38
In short — BioMarin Pharmaceutical trades at 147.0× earnings (P/E), 8.2× forward, with a net margin of 2.1 % and revenue growth of +20 %. Read: Cheap for the growth (P/E 8 for ~20% growth (PEG 0.4)).
Is BioMarin Pharmaceutical stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$54.38+3.6% over range
Oct 14, 25low $49.67 · high $70.24Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
85% recommend buying · 13 analysts
Valuation : Cheap for the growth — P/E 8 for ~20% growth (PEG 0.4)
Valuation
147.0
P/E (price/earnings)
8.2
Forward P/E
—
PEG
1.7
Price/book (P/B)
$10.5B
Market cap
0.37
EPS
Profitability & growth
2.1 %
Net margin
+20 %
Revenue growth
-81 %
Earnings growth
$4.2B
Total debt
BioMarin Pharmaceutical income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $2.1B | $142M | 6.8 % |
| 2023 | $2.4B | $168M | 6.9 % |
| 2024 | $2.9B | $427M | 15.0 % |
| 2025 | $3.2B | $349M | 10.8 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is BioMarin Pharmaceutical's P/E and is the stock undervalued? What's a good P/E?
BioMarin Pharmaceutical's P/E is 147.0 (forward 8.2). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is BioMarin Pharmaceutical profitable?
BioMarin Pharmaceutical has a net margin of 2.1 % (EPS 0.37). The company is profitable.
Is BMRN stock expensive?
Our read: "Cheap for the growth" — P/E 8 for ~20% growth (PEG 0.4). Cross-check with growth and sector.
💬 A question about BioMarin Pharmaceutical? The JPI assistant answers using our backtest data.
Keep exploring BioMarin Pharmaceutical